CORRECTING and REPLACING Compugen Fourth Quarter 2012 Conference Call Scheduled for Wednesday, February 20, 2013 at 10:00 AM ...
12 Febrero 2013 - 3:37PM
Business Wire
Headline of release should read: Compugen
Fourth Quarter 2012 Conference Call Scheduled for Wednesday,
February 20, 2013 at 10:00 AM EST
The release reads:
COMPUGEN FOURTH QUARTER 2012 CONFERENCE CALL
SCHEDULED FOR WEDNESDAY, FEBRUARY 20, 2013 AT 10:00 AM EST
Compugen Ltd. (NASDAQ: CGEN) today announced that the Company
will host a conference call at 10:00 AM EST on Wednesday, February
20, 2013 to review fourth quarter 2012 results. The quarterly
results will be released on the Company’s website (www.cgen.com),
prior to the conference call.
To access the conference call, please dial 1-888-668-9141 from
the US, or +972-3-918-0609 internationally. The call will also be
available via live webcast through Compugen’s website, located at
the following link.
A replay of the conference call will be available approximately
two hours after the completion of the live conference call. To
access the replay, please dial 1-888-782-4291 from the US or
+972-3-9255-904 internationally. The replay will be available
through February 23, 2013.
About Compugen
Compugen is a leading drug discovery company focused on
therapeutic proteins and monoclonal antibodies to address important
unmet needs in the fields of immunology and oncology. The Company
utilizes a broad and continuously growing integrated infrastructure
of proprietary scientific understandings and predictive platforms,
algorithms, machine learning systems and other computational
biology capabilities for the in silico (by computer)
prediction and selection of product candidates, which are then
advanced in its Pipeline Program. The Company's business model
includes collaborations covering the further development and
commercialization of selected product candidates from its Pipeline
Program and various forms of research and discovery agreements, in
both cases providing Compugen with potential milestone payments and
royalties on product sales or other forms of revenue sharing. In
2012, Compugen established operations in California for the
development of oncology and immunology monoclonal antibody
therapeutic candidates against Compugen drug targets. For
additional information, please visit Compugen's corporate website
at www.cgen.com.
Compugen (NASDAQ:CGEN)
Gráfica de Acción Histórica
De Jun 2024 a Jul 2024
Compugen (NASDAQ:CGEN)
Gráfica de Acción Histórica
De Jul 2023 a Jul 2024